CN1280288C - 作为1型纤溶酶原激活物抑制剂(pai－1)的抑制剂的取代萘基吲哚衍生物 - Google Patents

作为1型纤溶酶原激活物抑制剂(pai－1)的抑制剂的取代萘基吲哚衍生物 Download PDF

Info

Publication number
CN1280288C
CN1280288C CNB028123913A CN02812391A CN1280288C CN 1280288 C CN1280288 C CN 1280288C CN B028123913 A CNB028123913 A CN B028123913A CN 02812391 A CN02812391 A CN 02812391A CN 1280288 C CN1280288 C CN 1280288C
Authority
CN
China
Prior art keywords
compound
alkyl
naphthyl
pharmaceutically acceptable
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028123913A
Other languages
English (en)
Chinese (zh)
Other versions
CN1549814A (zh
Inventor
S·C·迈尔
E·G·贡德尔森
H·M·埃洛克达
D·L·克兰达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1549814A publication Critical patent/CN1549814A/zh
Application granted granted Critical
Publication of CN1280288C publication Critical patent/CN1280288C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
CNB028123913A 2001-06-20 2002-06-18 作为1型纤溶酶原激活物抑制剂(pai－1)的抑制剂的取代萘基吲哚衍生物 Expired - Fee Related CN1280288C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29965101P 2001-06-20 2001-06-20
US60/299,651 2001-06-20

Publications (2)

Publication Number Publication Date
CN1549814A CN1549814A (zh) 2004-11-24
CN1280288C true CN1280288C (zh) 2006-10-18

Family

ID=23155676

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028123913A Expired - Fee Related CN1280288C (zh) 2001-06-20 2002-06-18 作为1型纤溶酶原激活物抑制剂(pai－1)的抑制剂的取代萘基吲哚衍生物

Country Status (25)

Country Link
US (4) US6800654B2 (enExample)
EP (1) EP1397356B1 (enExample)
JP (1) JP4520144B2 (enExample)
KR (1) KR20040007744A (enExample)
CN (1) CN1280288C (enExample)
AR (1) AR036101A1 (enExample)
AT (1) ATE431346T1 (enExample)
AU (1) AU2002316533B2 (enExample)
BR (1) BR0210504A (enExample)
CA (1) CA2448798C (enExample)
CO (1) CO5540286A2 (enExample)
DE (1) DE60232328D1 (enExample)
EA (1) EA009696B1 (enExample)
EC (1) ECSP034904A (enExample)
ES (1) ES2325733T3 (enExample)
HU (1) HUP0400233A3 (enExample)
IL (1) IL159449A0 (enExample)
MX (1) MXPA03011522A (enExample)
NO (2) NO326316B1 (enExample)
NZ (1) NZ530312A (enExample)
PL (1) PL367525A1 (enExample)
TW (1) TWI224101B (enExample)
UA (1) UA78708C2 (enExample)
WO (1) WO2003000684A1 (enExample)
ZA (1) ZA200400380B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7078429B2 (en) * 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
EP1569899B1 (en) * 2002-12-10 2006-06-28 Wyeth Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052854A2 (en) * 2002-12-10 2004-06-24 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052856A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP4390460B2 (ja) * 2003-02-21 2009-12-24 株式会社静岡カフェイン工業所 オキサゾール誘導体
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7411083B2 (en) * 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7115815B2 (en) * 2003-10-31 2006-10-03 Adc Telecommunications, Inc. Cable utilizing varying lay length mechanisms to minimize alien crosstalk
MX2007002178A (es) * 2004-08-23 2007-04-02 Wyeth Corp Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares.
WO2006023866A2 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
WO2006023864A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
KR20070103744A (ko) * 2005-01-27 2007-10-24 와이어쓰 치환된 나프틸인돌 유도체를 제조하기 위한 방법 및 화합물
US7683091B2 (en) * 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
TW200744585A (en) * 2006-02-27 2007-12-16 Wyeth Corp Inhibitors of PAI-1 for treatment of muscular conditions
WO2008044729A1 (fr) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Dérivé d'acide carboxylique
US7884234B2 (en) * 2006-10-12 2011-02-08 Institute Of Medicinal Molecular Design, Inc. N-phenyloxamide derivatives
US9120744B2 (en) 2007-04-16 2015-09-01 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
US8759327B2 (en) 2007-04-16 2014-06-24 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
US20100324091A1 (en) 2007-06-27 2010-12-23 Kowa Company, Ltd. Pyrazolone Derivative
WO2009054439A1 (ja) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Pai-1産生抑制剤
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
CA2720096A1 (en) 2008-04-11 2009-10-15 Institute Of Medicinal Molecular Design, Inc. Pai-1 inhibitor
DK2914575T3 (da) 2012-10-31 2021-01-18 Univ Michigan Regents Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf
CN106890324A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
CN118221546A (zh) 2017-07-27 2024-06-21 密歇根大学董事会 纤维蛋白溶酶原活化物抑制因子-1（pai-1）抑制剂和使用方法
CN114057623B (zh) * 2021-12-07 2023-07-21 湖南第一师范学院 一种n-萘基吲哚衍生物及其合成方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026325A (en) * 1959-01-26 1962-03-20 Upjohn Co 5-hydroxy-alpha-alkyltryptophans
US3476770A (en) * 1967-04-14 1969-11-04 Parke Davis & Co 2-methyl-7-phenylindole-3-acetic acid compounds
GB1321433A (en) 1968-01-11 1973-06-27 Roussel Uclaf 1,2,3,6-tetrasubstituted indoles
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
FR2244499A1 (en) 1973-06-07 1975-04-18 Delalande Sa Indol-3-ylformaldoxime carbamates - for treating anxiety epilepsy, cardiac arrhythmias, asthma, intestinal spasm, peptic ulcer, cardiac insufficiency
US4519909A (en) * 1977-07-11 1985-05-28 Akzona Incorporated Microporous products
DE3147276A1 (de) 1981-11-28 1983-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von indolderivaten, deren verwendung als wertvolle zwischenprodukte und neue 4-hydroxyindole
FR2525474A1 (fr) * 1982-04-26 1983-10-28 Roussel Uclaf Nouvelle forme pharmaceutique orale de clometacine
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
US4859538A (en) * 1986-11-20 1989-08-22 Ribi Hans O Novel lipid-protein compositions and articles and methods for their preparation
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
IL95584A (en) 1989-09-07 1995-03-15 Abbott Lab Indole-, benzoporene- and benzothiophene compounds including lipoxygenase-inhibiting compounds and pharmaceutical compounds containing them
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5151435A (en) 1991-04-08 1992-09-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating an indole or dihydroindole
IL101785A0 (en) 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
DE4242675A1 (de) 1992-12-17 1994-06-23 Basf Ag Neue Hydroxyiminoalkylindolcarbonsäure-Derivate, ihre Herstellung und Verwendung
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
IL109568A0 (en) 1993-05-19 1994-08-26 Fujisawa Pharmaceutical Co Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
EP0820441B1 (en) 1995-04-10 2002-06-26 Fujisawa Pharmaceutical Co., Ltd. INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
US5728724A (en) 1995-08-17 1998-03-17 Eli Lilly And Company Benzothiophene compounds
WO1997009308A1 (en) 1995-09-01 1997-03-13 Eli Lilly And Company Indolyl neuropeptide y receptor antagonists
DE19543639A1 (de) 1995-11-23 1997-05-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
GB9609641D0 (en) 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
CA2207083A1 (en) 1996-07-15 1998-01-15 Brian William Grinnell Benzothiophene compounds, and uses and formulations thereof
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
EP0822185A1 (en) 1996-07-31 1998-02-04 Pfizer Inc. B-3-adrenergic agonists as antidiabetic and antiobesity agents
JP2000516958A (ja) 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
DE19753522A1 (de) 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
GEP20032920B (en) 1998-02-25 2003-03-25 Genetics Inst Inhibitors of Phospholipase Enzymes
ID27280A (id) 1998-02-25 2001-03-22 Genetics Inst Inhibitor-inhibitor dari enzim-enzim fosfolipase
EE200000522A (et) 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
SE9800836D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
AP2000001929A0 (en) 1998-03-31 2000-09-30 Inst For Pharm Discovery Inc Substituted indolealkanoic acids.
FR2777886B1 (fr) 1998-04-27 2002-05-31 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6110963A (en) * 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6232322B1 (en) * 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6251936B1 (en) * 1998-05-12 2001-06-26 American Home Products Corporation Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
HRP20000767A2 (en) 1998-05-12 2001-10-31 American Home Prod Benzothiophenes, benzofurans and indoles useful in the treatment of insulin resistance and hyperglycemia
EP1077965A1 (en) 1998-05-12 2001-02-28 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
WO2000031045A1 (en) * 1998-11-20 2000-06-02 Torii Pharmaceutical Co., Ltd. Naphthalene derivatives
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
US6479524B1 (en) * 1998-12-16 2002-11-12 Boehringer Ingelheim Pharma Kg Substituted aryl and heteroaryl derivatives, their production and their use as medicines
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
AU2319100A (en) 1999-01-28 2000-08-18 Nippon Shinyaku Co. Ltd. Amide derivatives and drug compositions
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
NZ515087A (en) 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
GB9919413D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
FR2799756B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19963178A1 (de) * 1999-12-27 2001-07-05 Gruenenthal Gmbh Substituierte Indol-Mannichbasen
DE10031281A1 (de) * 2000-06-27 2002-01-10 Creavis Tech & Innovation Gmbh Polyelektrolytbeschichteter, stoffdurchlässiger Verbundwerkstoff, Verfahren zu dessen Herstellung und die Verwendung des Verbundwerkstoffes
IL154981A0 (en) 2000-10-10 2003-10-31 Smithkline Beecham Corp Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US6808908B2 (en) * 2001-05-30 2004-10-26 Porex Technologies Corporation Functionalized porous substrate for binding chemical and biological moieties
FR2825706B1 (fr) * 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7074817B2 (en) * 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI240723B (en) * 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7456025B2 (en) * 2001-08-28 2008-11-25 Porex Corporation Sintered polymer membrane for analyte detection device
KR100810468B1 (ko) 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체
CN1642910A (zh) 2002-02-12 2005-07-20 威斯康星校友研究基金会 用于ah受体作为配体的吲哚噻唑化合物的合成
EP1495016A2 (en) 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US7078429B2 (en) * 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
WO2004052856A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052854A2 (en) * 2002-12-10 2004-06-24 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
EP1569899B1 (en) * 2002-12-10 2006-06-28 Wyeth Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US20050215626A1 (en) * 2003-09-25 2005-09-29 Wyeth Substituted benzofuran oximes
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles

Also Published As

Publication number Publication date
NO326316B1 (no) 2008-11-10
CA2448798A1 (en) 2003-01-03
ATE431346T1 (de) 2009-05-15
EA200400054A1 (ru) 2004-04-29
JP2004534825A (ja) 2004-11-18
US6939886B2 (en) 2005-09-06
JP4520144B2 (ja) 2010-08-04
UA78708C2 (en) 2007-04-25
HUP0400233A2 (hu) 2004-08-30
EA009696B1 (ru) 2008-02-28
US20060014725A1 (en) 2006-01-19
PL367525A1 (en) 2005-02-21
NO20035635D0 (no) 2003-12-17
US7629377B2 (en) 2009-12-08
MXPA03011522A (es) 2004-03-19
ECSP034904A (es) 2004-01-28
HUP0400233A3 (en) 2008-10-28
WO2003000684A1 (en) 2003-01-03
NZ530312A (en) 2005-05-27
AR036101A1 (es) 2004-08-11
EP1397356B1 (en) 2009-05-13
AU2002316533B2 (en) 2007-10-18
US20040266733A1 (en) 2004-12-30
BR0210504A (pt) 2004-05-18
CO5540286A2 (es) 2005-07-29
US7351730B2 (en) 2008-04-01
IL159449A0 (en) 2004-06-01
ES2325733T3 (es) 2009-09-15
US20080182883A1 (en) 2008-07-31
US6800654B2 (en) 2004-10-05
ZA200400380B (en) 2006-06-28
TWI224101B (en) 2004-11-21
KR20040007744A (ko) 2004-01-24
CA2448798C (en) 2010-07-20
US20030032626A1 (en) 2003-02-13
NO20084390L (no) 2003-12-17
CN1549814A (zh) 2004-11-24
DE60232328D1 (de) 2009-06-25
EP1397356A1 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
CN1549814A (zh) 作为1型纤溶酶原激活物抑制剂(pai-1)的抑制剂的取代萘基吲哚衍生物
CN1726029A (zh) 作为纤溶酶原激活物抑制剂 － 1(pa i－1 )的抑制剂的取代二氢吡喃并吲哚－3, 4－二酮衍生物和3－氧代乙酸取代的2－羟基甲基吲哚衍生物
CN1198807C (zh) 作为环加氧酶－2抑制剂的5－芳基－1h－1,2,4－三唑化合物及含有它们的药物组合物
CN1168709C (zh) 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸的α-羟基、-氨基和卤代衍生物
CN1723198A (zh) 用作纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的芳基、芳氧基和烷氧基取代的1h－吲哚－3－基乙醛酸衍生物
CN1653047A (zh) 抗炎症药物单环芳酰吡啶酮
CN87105680A (zh) 咪唑化合物及其制备方法，和包含该化合物的药物组合物
CN1795174A (zh) 新型取代的3－硫吲哚
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
CN1678306A (zh) 在炎性、变应性和增生性疾病中用作糖皮质激素模拟物的3－(磺酰氨基乙基)－吲哚衍生物
CN1909902A (zh) 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物
CN1906189A (zh) 用于治疗呼吸系统疾病的1－乙酸－吲哚、－吲唑和－苯并咪唑衍生物
CN1845909A (zh) 作为嗜中性白细胞弹性蛋白酶抑制剂的喹喔啉衍生物及它们的用途
CN1203587A (zh) 新的杂环衍生物及其医药用途
CN1168720C (zh) 芳基链烷酰基哒嗪化合物
CN1812977A (zh) 取代羧酸
CN1315950A (zh) 作为5－ht4受体拮抗剂的二氢苯并二噁烯羧酰胺与酮衍生物
CN1119856A (zh) Hiv逆转录酶抑制剂
CN1794987A (zh) 具有提高的抗炎、抗血栓形成和抗血小板活性的作为降胆固醇药的氟伐他汀、普伐他汀、西立伐他汀、阿托伐他汀和罗苏伐他汀的硝基氧基衍生物
CN1304401A (zh) calcilytic化合物
CN1922162A (zh) 烷基哌嗪－和烷基高哌嗪－羧酸酯衍生物、其制备方法及其作为faah酶抑制剂的用途
CN1791409A (zh) 作为 p p a r调节剂的 ( 3 －{ 3'－ [ ( 2 , 4 －双 －三氟甲基 －苄基)－ ( 5 －乙基 －嘧啶 － 2 －基 )－氨基 ]－丙氧基} －苯基) －乙酸及相关化合物以及治疗代谢失调的方法
CN101044136A (zh) 作为pai－1抑制剂的吡咯基－萘基酸
CN101039936A (zh) 作为i－型纤溶酶原激活剂抑制剂(pai－1)调节剂用于治疗血栓形成和心血管疾病的唑基－萘基酸
CN1849306A (zh) 基质金属蛋白酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061018

Termination date: 20100618